Combination therapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are aged 18 to 75
- Have been diagnosed with rectal cancer that has not spread to distant organs
- Are generally fit for treatment (able to care for yourself and carry out daily activities)
- Have a specific tumor marker called pMMR or MSS
- Have not had previous treatment for rectal cancer (surgery, chemo, or radiation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a combination of radiation therapy, chemotherapy, and immunotherapy given before surgery for rectal cancer that has high-risk features. The goal is to shrink the tumor and improve outcomes for patients with this aggressive form of cancer.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.